Crohn's Disease and Colitis Trial, Recruiting NCT04973423 Sponsor: University Hospital, Clermont-Ferrand Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT04973423
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with Crohn's disease
  • People whose Crohn's disease is causing active symptoms, measured using a standard scoring tool called the CDAI, with a score above 150
  • People who have signs of active inflammation confirmed by both a stool test (fecal calprotectin level above 250) and an MRI scan showing disease activity
  • People whose doctor has determined that biological therapy (a type of medication that targets the immune system) is needed as part of their treatment
  • People who are able to give their informed consent to take part in research
  • People who are enrolled in the French Social Security system

Who may not be able to join:

  • People with severe blockage or obstruction symptoms in their digestive tract
  • People with an uncontrolled abscess (a pocket of infection) inside the abdomen
  • People whose Crohn's disease affects only the area around the anus and perineum, with no other areas involved
  • People taking part in a program to prevent Crohn's disease from returning after surgery
  • People who have a temporary or permanent stoma (a surgical opening in the abdomen for waste)
  • People who have had their entire colon surgically removed
  • People who are unable to have an MRI scan for any medical reason
  • Women who are pregnant or breastfeeding
  • Adults who are under legal protection measures such as guardianship or curatorship (confirm with trial site)
  • People who do not wish to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 04 73 75 11 95

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 March 2022
Est. completion
21 March 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Proportion of months spent in clinical remission

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov